These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 18454258)

  • 21. The intrarenal renin-angiotensin system and diabetic nephropathy.
    Carey RM; Siragy HM
    Trends Endocrinol Metab; 2003 Aug; 14(6):274-81. PubMed ID: 12890592
    [TBL] [Abstract][Full Text] [Related]  

  • 22. RAAS inhibitors directly reduce diabetes-induced renal fibrosis via growth factor inhibition.
    Koszegi S; Molnar A; Lenart L; Hodrea J; Balogh DB; Lakat T; Szkibinszkij E; Hosszu A; Sparding N; Genovese F; Wagner L; Vannay A; Szabo AJ; Fekete A
    J Physiol; 2019 Jan; 597(1):193-209. PubMed ID: 30324679
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers for diabetic nephropathy: a retrospective comparison.
    Robles NR; Romero B; Fernandez-Carbonero E; Sánchez-Casado E; Cubero JJ
    J Renin Angiotensin Aldosterone Syst; 2009 Dec; 10(4):195-200. PubMed ID: 20026868
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure].
    Bernadet-Monrozies P; Rostaing L; Kamar N; Durand D
    Presse Med; 2002 Nov; 31(36):1714-20. PubMed ID: 12467154
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Angiotensin II and its receptors in the diabetic kidney.
    Burns KD
    Am J Kidney Dis; 2000 Sep; 36(3):449-67. PubMed ID: 10977776
    [TBL] [Abstract][Full Text] [Related]  

  • 26. ACE insertion/deletion polymorphism and diabetic nephropathy: clinical implications of genetic information.
    Ha SK
    J Diabetes Res; 2014; 2014():846068. PubMed ID: 25587546
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: pathophysiology and indications.
    Wolf G; Ritz E
    Kidney Int; 2005 Mar; 67(3):799-812. PubMed ID: 15698420
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment effects of renin-angiotensin aldosterone system blockade on kidney failure and mortality in chronic kidney disease patients.
    Vejakama P; Ingsathit A; McKay GJ; Maxwell AP; McEvoy M; Attia J; Thakkinstian A
    BMC Nephrol; 2017 Nov; 18(1):342. PubMed ID: 29187194
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prevention of loss of renal function over time in patients with diabetic nephropathy.
    Barnett A
    Am J Med; 2006 May; 119(5 Suppl 1):S40-7. PubMed ID: 16563947
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genetic polymorphisms of the renin-angiotensin-aldosterone system in end-stage renal disease.
    Lovati E; Richard A; Frey BM; Frey FJ; Ferrari P
    Kidney Int; 2001 Jul; 60(1):46-54. PubMed ID: 11422735
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Renoprotection by blockade of the renin-angiotensin-aldosterone system in diabetic and non-diabetic chronic kidney disease. Specific involvement of intra-renal angiotensin-converting enzyme activity in therapy resistance?
    Vogt L; Kocks MJ; Laverman GD; Navis G
    Minerva Med; 2004 Oct; 95(5):395-409. PubMed ID: 15467515
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Disputes in the Treatment of Diabetic Nephropathy: The Dual Blockade of Renin-Angiotensin System.
    Grolla E; Bonanni L; Cutolo A; Presotto F; Dalla Vestra M
    Exp Clin Endocrinol Diabetes; 2016 Jun; 124(6):361-6. PubMed ID: 27219891
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Worsening renal failure in older chronic kidney disease patients with renal artery stenosis concurrently on renin angiotensin aldosterone system blockade: a prospective 50-month Mayo-Health-System clinic analysis.
    Onuigbo MA; Onuigbo NT
    QJM; 2008 Jul; 101(7):519-27. PubMed ID: 18375475
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Preventing end stage renal disease in diabetic patients--genetic aspect (part I).
    Jacobsen PK
    J Renin Angiotensin Aldosterone Syst; 2005 Mar; 6(1):1-14. PubMed ID: 16088846
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The renin-angiotensin system and diabetic nephropathy.
    Gurley SB; Coffman TM
    Semin Nephrol; 2007 Mar; 27(2):144-52. PubMed ID: 17418683
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The rate of progression of type 2 diabetes mellitus to end stage renal disease - A single centred retrospective study from Malaysia.
    Ng YP; Ahmed R; Ooi GS; Lau CY; Balasubramanian GP; Yap CH
    Diabetes Metab Syndr; 2018 Nov; 12(6):1025-1030. PubMed ID: 30168425
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and Safety of Dual Blockade of the Renin-Angiotensin-Aldosterone System in Diabetic Kidney Disease: A Meta-Analysis.
    Feng Y; Huang R; Kavanagh J; Li L; Zeng X; Li Y; Fu P
    Am J Cardiovasc Drugs; 2019 Jun; 19(3):259-286. PubMed ID: 30737754
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Individualized prediction of the effect of angiotensin receptor blockade on renal and cardiovascular outcomes in patients with diabetic nephropathy.
    van der Sande NG; Dorresteijn JA; Visseren FL; Dwyer JP; Blankestijn PJ; van der Graaf Y; Heerspink HL
    Diabetes Obes Metab; 2016 Nov; 18(11):1120-1127. PubMed ID: 27337598
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Investigational drugs for diabetic nephropathy.
    Cortinovis M; Cattaneo D; Perico N; Remuzzi G
    Expert Opin Investig Drugs; 2008 Oct; 17(10):1487-500. PubMed ID: 18808309
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL.
    de Zeeuw D; Remuzzi G; Parving HH; Keane WF; Zhang Z; Shahinfar S; Snapinn S; Cooper ME; Mitch WE; Brenner BM
    Kidney Int; 2004 Jun; 65(6):2309-20. PubMed ID: 15149345
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.